1. 179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT). (December 2022) Authors: Forster, M.D.; Cave, J.; Greystoke, A.; Plummer, R.; Spicer, J.; Thistlethwaite, F.; Turajlic, S.; Craig, A.; Newton, K.; Saggese, M.; Quezada, S.; Peggs, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. Issue 3 (September 2015) Authors: Rasco, D.W.; Middleton, M.R.; Gonzalez, R.; Corrie, P.; Pavlick, A.; Lorigan, P.; Plummer, R.; Gore, M.; Herbert, C.; Agarwala, S.S.; Logan, T.F.; Khleif, S.N.; Papadopoulos, K.P.; Rangachari, L.; Suri, A.; Xu, Q.; Kneissl, M.; Bozón, V.; Olszanski, A.J. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 312 A phase I dose escalation study to assess the safety tolerability and pharmacokinetics of ETS2101 in patients (pts) with advanced solid tumours. (September 2015) Authors: Plummer, R.; Anthoney, A.; Evans, J.; Haris, N.; D'Archangelo, M.; Slater, S.; Campbell, S.; Brindley, C.; Self, S.; McKeown, P.; Lavin, S.; Hynes, D.; Flores, M.V.; Pedret-Dunn, A.; Laffranchi, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). (September 2015) Authors: Michalarea, V.; Lopez, J.; Lorente, D.; Carreira, S.; Hassam, H.; Parmar, M.; Turner, A.; Hall, E.; Fandos, S. Serrano; Decordova, S.; Swales, K.; Ruddle, R.; Raynaud, F.; Tunariu, N.; Stephens, C.M.; Molife, L.R.; Banerji, U.; Plummer, R.; Bono, J. De; Yap, T.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018) Authors: Arkenau, H.-T.; Italiano, A.; Mak, G.; Toulmonde, M.; Baird, R.D.; Garcia-Corbacho, J.; Plummer, R.; Flynn, M.; Forster, M.; Wilson, R.H.; Tosi, D.; Adenis, A.; Donaldson, K.; Posner, J.; Kawabata, I.; Arimura, A.; Deva, S.; Spicer, J. Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Autophagy modulation in MEK inhibitor‐resistant melanoma. (1st February 2019) Authors: Verykiou, S.; Alexander, M.; Edwards, N.; Plummer, R.; Chaudhry, B.; Lovat, P.E.; Hill, D.S. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Autophagy modulation in MEK inhibitor‐resistant melanoma. (4th February 2019) Authors: Verykiou, S.; Alexander, M.; Edwards, N.; Plummer, R.; Chaudhry, B.; Lovat, P.E.; Hill, D.S. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: e42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors. (1st August 2021) Authors: Gault, A.; Anderson, A.E.; Plummer, R.; Stewart, C.; Pratt, A.G.; Rajan, N. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors. (1st February 2021) Authors: Gault, A.; Anderson, A.E.; Plummer, R.; Stewart, C.; Pratt, A.G.; Rajan, N. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Diffusion-weighted MRI for Early Response Assessment in the Treatment of Bladder Cancer. Issue 3 (March 2018) Authors: Pearson, R.; Pieniazek, P.; Thelwall, P.; Maxwell, R.; Plummer, R.; Frew, J. Journal: Clinical oncology Issue: Volume 30:Issue 3(2018) Page Start: 193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗